dexrazoxane

P3, N=236, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Mar 2027 --> Mar 2026

The risk-based approach and use of targeted therapies in CHIP-AML22 illustrate a shift toward more personalized treatment. Besides improving event-free survival, this study aims to contribute to the international consensus on strategies to reduce toxicity for all patients. The design of this study provides a dynamic framework, allowing for the potential introduction of emerging therapeutic options in the future.

P2, N=60, Not yet recruiting, Beth Israel Deaconess Medical Center

P2, N=42, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Sep 2026 --> Mar 2026

Translational advances include established cardioprotective approaches such as dexrazoxane and liposomal formulations, alongside investigational strategies-including SGLT2 inhibitors, OCT3 blockade, and RARG agonists-that require prospective validation. Complementary efforts to overcome resistance encompass nanomedicine-based delivery, STAT3 inhibition, and RNA-directed therapeutics. By converging molecular mechanisms, pharmacogenomic insights, and biomarker discovery, this review outlines precision strategies to sustain doxorubicin benefit while minimizing cardiovascular harm.

P2, N=65, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2026 --> Oct 2027 | Trial primary completion date: Oct 2026 --> Oct 2027

P=N/A, N=420, Recruiting, Children's Oncology Group | Trial completion date: Dec 2025 --> Dec 2026

P3, N=236, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027

These strategies highlight recent data supporting the emerging cardioprotective role of exercise training, as well as the use of SGLT2 inhibitors, ACE inhibitors, angiotensin receptor blockers, sacubitril/valsartan, beta-blockers, mineralocorticoid receptor antagonists, statins and dexrazoxane. We present a comprehensive synthesis emphasizing the critical role of cardio-oncology in identifying patients at high risk, understanding clinical outcomes, and implementing practical, evidence-based strategies. Our findings underscore the need for proactive cardiovascular risk management to enhance long-term care in oncology patients.

DSS confers cardioprotection against DOX-induced injury by disrupting the vicious circle formed by ROS and JNK, which mediated impairment of mitochondrial quality control, attenuating oxidative stress, and reducing apoptosis. These findings highlight DSS as a promising therapeutic candidate for mitigating chemotherapy-associated cardiotoxicity.

P1, N=30, Recruiting, Andrew E. Place, MD | Active, not recruiting --> Recruiting | N=13 --> 30 | Trial completion date: Jul 2028 --> Jul 2030 | Trial primary completion date: Jul 2026 --> Jul 2028

Phytochemicals derived from Mentha arvensis demonstrate potential as dual-action agents capable of mitigating doxorubicininduced cardiotoxicity while preserving anticancer activity. However, when used alone, these compounds exhibited only moderate therapeutic potential. Combinatorial strategies involving Dexa may enhance cardioprotective efficacy while reducing associated limitations, possibly through modulation of ferroptosis-related pathways. Nevertheless, rigorous experimental validation remains essential. Future studies should employ well-established in vivo oncogenic cardiotoxicity models incorporating Dox, Dexa, and phytochemicals concurrently to elucidate shared molecular targets and confirm therapeutic efficacy against both cancer and DIC.